Campbell & CO Investment Adviser LLC Acquires 2,102 Shares of Intuitive Surgical, Inc. $ISRG

Key Points

• Campbell & CO Investment Adviser LLC increased its holdings in Intuitive Surgical, Inc. by 125.4% in Q1, now owning 3,778 shares valued at approximately $1.87 million.
• A majority of analysts rate Intuitive Surgical as a "Moderate Buy", with an average target price of $595.95 despite recent stock fluctuations.
• Insider trading activity included significant sales, with SVP Mark Brosius selling shares leading to a 19.23% decrease in his ownership, indicating potential concerns among insiders.

Campbell & CO Investment Adviser LLC raised its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 125.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,778 shares of the medical equipment provider's stock after buying an additional 2,102 shares during the period. Campbell & CO Investment Adviser LLC's holdings in Intuitive Surgical were worth $1,871,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Chilton Capital Management LLC boosted its holdings in Intuitive Surgical by 614.3% in the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 43 shares in the last quarter. Parvin Asset Management LLC bought a new stake in Intuitive Surgical in the fourth quarter worth $26,000. Global Financial Private Client LLC boosted its holdings in Intuitive Surgical by 253.3% during the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 38 shares during the period. Elite Financial Inc. bought a new stake in Intuitive Surgical during the first quarter valued at about $26,000. Finally, LFA Lugano Financial Advisors SA bought a new stake in Intuitive Surgical during the first quarter valued at about $30,000. Institutional investors and hedge funds own 83.64% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. BTIG Research upped their price target on shares of Intuitive Surgical from $566.00 to $571.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Erste Group Bank reaffirmed a "hold" rating on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Wall Street Zen raised shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Citigroup reaffirmed a "buy" rating and set a $650.00 price objective (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $595.00 price objective (up previously from $575.00) on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Thirteen analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $595.95.

Intuitive Surgical Stock Up 0.6%

ISRG stock traded up $2.69 during midday trading on Thursday, reaching $473.84. The company's stock had a trading volume of 1,548,672 shares, compared to its average volume of 1,988,124. The business's 50-day simple moving average is $501.17 and its 200-day simple moving average is $518.82. The stock has a market cap of $169.86 billion, a PE ratio of 66.09, a price-to-earnings-growth ratio of 4.94 and a beta of 1.59. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, topping the consensus estimate of $1.93 by $0.26. The company had revenue of $2.44 billion for the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The business's revenue for the quarter was up 21.4% compared to the same quarter last year. During the same period last year, the business posted $1.78 earnings per share. As a group, equities analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Intuitive Surgical news, EVP Myriam Curet sold 4,500 shares of Intuitive Surgical stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the sale, the executive vice president owned 353 shares in the company, valued at $173,845.44. The trade was a 92.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mark Brosius sold 216 shares of the business's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the sale, the senior vice president directly owned 907 shares in the company, valued at $510,740.77. The trade was a 19.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 15,839 shares of company stock valued at $7,896,972. Company insiders own 0.70% of the company's stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.